Association of prestroke metformin use, stroke severity, and thrombolysis outcome.

Westphal, Laura P; Widmer, Roni; Held, Ulrike; Steigmiller, Klaus; Hametner, Christian; Ringleb, Peter; Curtze, Sami; Martinez-Majander, Nicolas; Tiainen, Marjaana; Nolte, Christian H; Scheitz, Jan F; Erdur, Hebun; Polymeris, Alexandros A; Traenka, Christopher; Eskandari, Ashraf; Michel, Patrik; Heldner, Mirjam R.; Arnold, Marcel; Zini, Andrea; Vandelli, Laura; ... (2020). Association of prestroke metformin use, stroke severity, and thrombolysis outcome. Neurology, 95(4), e362-e373. American Academy of Neurology 10.1212/WNL.0000000000009951

Text Westphal, 2020, Association of pre_stroke metformin use_2.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (654kB)

OBJECTIVE

To evaluate whether pretreatment with metformin (MET) is associated with less stroke severity and better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919 patients with stroke with type 2 diabetes mellitus in a multicenter exploratory analysis.

METHODS

Data from patients with diabetes and ischemic stroke treated with IVT were collected within the European Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score matching (PSM) to obtain balanced baseline characteristics of patients treated with and without MET.

RESULTS

Of 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET before stroke (MET+), whereas 1,162 (61%) had not (MET-). MET+ patients were younger with a male preponderance. Hypercholesterolemia and pretreatment with statins, antiplatelets, or antihypertensives were more common in the MET+ group. After PSM, the 2 groups were well balanced with respect to demographic and clinical aspects. Stroke severity on admission (NIH Stroke Scale 10.0 ± 6.7 vs 11.3 ± 6.5), 3-month degree of independence on modified Rankin Scale (2 [interquartile range (IQR) 1.0-4.0] vs 3 [IQR 1.0-4.0]), as well as mortality (12.5% vs 18%) were significantly lower in the MET+ group. The frequency of symptomatic intracerebral hemorrhages did not differ between groups. HbA1c levels were well-balanced between the groups.

CONCLUSIONS

Patients with stroke and diabetes on treatment with MET receiving IVT had less severe strokes on admission and a better functional outcome at 3 months. This suggests a protective effect of MET resulting in less severe strokes as well as beneficial thrombolysis outcome.

Interest & Impact

Downloads

1 since deposited on 13 Nov 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item